H. Lundbeck A/S
HLUN-A
Ранг среди акций
#2991
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Цена акции
$7.41
Рыночная капитализация
$6.17B
Изменение (1 день)
3.44%
Изменение (1 год)
33.63%
Страна
DK
Торговля H. Lundbeck A/S (HLUN-A)
Категория
Healthcare
EPS для H. Lundbeck A/S (HLUN-A)
EPS по состоянию на June 2026 TTM: $0.62
Согласно последним финансовым отчетам и цене акций H. Lundbeck A/S, текущий EPS компании (TTM) составляет $0.62. В конце 2024 EPS компании составлял $0.44, больше, чем показателю 2023 года, равному $0.34.
История EPS компании H. Lundbeck A/S с 2004 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $0.62 | 21.73% |
| 2025 | $0.51 | 14.36% |
| 2024 | $0.44 | 29.33% |
| 2023 | $0.34 | 23.11% |
| 2022 | $0.28 | 9.41% |
| 2021 | $0.25 | -80.57% |
| 2020 | $1.31 | -35.12% |
| 2019 | $2.01 | -33.33% |
| 2018 | $3.02 | 41.16% |
| 2017 | $2.14 | 145.59% |
| 2016 | $0.87 | -120.64% |
| 2015 | $-4.22 | 3,227.66% |
| 2014 | $-0.13 | -115.78% |
| 2013 | $0.80 | -23.47% |
| 2012 | $1.05 | -48.14% |
| 2011 | $2.03 | -10.15% |
| 2010 | $2.25 | 14.02% |
| 2009 | $1.98 | -23.91% |
| 2008 | $2.60 | -19.22% |
| 2007 | $3.22 | 78.19% |
| 2006 | $1.81 | -12.40% |
| 2005 | $2.06 | 51.52% |
| 2004 | $1.36 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $2.41 | 288.21% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -16.24% |
US
|
